Cargando…

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

BACKGROUND: A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palacios, Santiago, Colli, Enrico, Regidor, Pedro-Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530969/ https://www.ncbi.nlm.nih.gov/pubmed/33008401 http://dx.doi.org/10.1186/s12905-020-01080-9

Ejemplares similares

Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone‐only pill
por: Palacios, Santiago, et al.
Publicado: (2019)

A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, Santiago, et al.
Publicado: (2019)

Correction to: A multicenter, double-blind, randomized trial on the bleeding profle of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, Santiago, et al.
Publicado: (2020)

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, S., et al.
Publicado: (2020)

Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial
por: Regidor, P.-A., et al.
Publicado: (2022)

A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers
por: Melka, Dace, et al.
Publicado: (2020)

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen()()
por: Kimble, Thomas, et al.
Publicado: (2020)

Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen
por: Regidor, Pedro-Antonio, et al.
Publicado: (2023)

An Oral Contraceptive Containing Estetrol 15 MG and Drospirenone 3 MG Has Limited Effects on Endocrine and Metabolic Parameters
por: Klipping, Christine, et al.
Publicado: (2021)

Bone health in estrogen-free contraception
por: Hadji, P., et al.
Publicado: (2019)

Correction to: Bone health in estrogen-free contraception
por: Hadji, P., et al.
Publicado: (2020)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People’s Republic of China: a comparison with international studies
por: Marr, Joachim, et al.
Publicado: (2015)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
por: Madigan, David, et al.
Publicado: (2018)

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone
por: Morimont, Laure, et al.
Publicado: (2022)

Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin
por: Bachmann, Gloria, et al.
Publicado: (2009)

The benefits of estetrol addition to drospirenone for contraception
por: Foidart, Jean Michel, et al.
Publicado: (2023)

Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone
por: Regidor, Pedro-Antonio, et al.
Publicado: (2017)

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
por: Breech, Lesley L, et al.
Publicado: (2010)

Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen
por: Mansour, Diana, et al.
Publicado: (2011)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Vitamin D serum levels in women using contraception containing drospirenone – a preliminary study
por: Ciebiera, Michał, et al.
Publicado: (2017)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
por: Wichianpitaya, Jirath, et al.
Publicado: (2013)

Preparation and Evaluation of Intravaginal Ring Containing Drospirenone
por: Zhang, Ying, et al.
Publicado: (2013)

THE CONTRACEPTIVE PILL
Publicado: (1965)

Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)
por: Podfigurna, A., et al.
Publicado: (2019)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
por: Tan, Jerry KL, et al.
Publicado: (2010)

Drospirenone and mood
por: Zuschmann, Andrew
Publicado: (2022)

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study
por: Grillo, Caterina Maria, et al.
Publicado: (2021)

A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial
por: Jaisamrarn, Unnop, et al.
Publicado: (2018)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia
por: Gemzell‐Danielsson, K, et al.
Publicado: (2021)

Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
por: Park, Bo Ra, et al.
Publicado: (2017)

Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008–2017
por: Lee, Yeri, et al.
Publicado: (2021)

Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol
por: Venter, Gerda, et al.
Publicado: (2021)

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data
por: Jick, Susan S, et al.
Publicado: (2011)

EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation
por: Diefenbach, Konstanze, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tdbcr69jqo06gdk3n03l6c0uba